FDA OKs Vutrisiran for hATTR Amyloidosis With Polyneuropathy

Vutrisiran, an RNAi therapeutic given by subcutaneous injection once every 3 months, significantly improved signs and symptoms of hATTR polyneuropathy in a phase 3 study.

Related Keywords

Johns Hopkins University ,Maryland ,United States ,Baltimore ,Michael Polydefkis ,Alnylam Pharmaceuticals ,Drug Administration ,Johns Hopkins University School Of Medicine ,Ionis Pharmaceuticals ,Alnylam Pharmaceuticals Inc ,Medscape Medical News ,Fast Track ,Johns Hopkins University School ,Alnylam Assist ,Medscape Medical ,Akcea Therapeutics ,Amyloidosis ,Transthyretin Related Amyloidosis ,Drug Development ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Neuropathy ,Cardiomyopathy ,Dyspnea ,Arthralgia ,Ainful Joint ,Joint Pain ,Disease Management ,